title: Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
abstract: Monoclonal antibodies that target immune checkpoints are undoubtedly changing the therapeutic landscape of different human malignancies. Here we comment on the effects of blocking cytotoxic T lymphocyte-associated protein 4 (CTLA4) by means of the monoclonal antibody tremelimumab in patients with refractory malignant mesothelioma, a deadly disease with no effective therapeutic options.
authors.affiliation: Medical Oncology and Immunotherapy; University Hospital of Siena; Istituto Toscano Tumori; Siena, Italy.
authors.forename: Luana
authors.initials: L
authors.lastname: Calabrò
authors.affiliation: Medical Oncology and Immunotherapy; University Hospital of Siena; Istituto Toscano Tumori; Siena, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Maio
keywords: anti-CTLA4 antibody; immunomodulating antibody; mesothelioma; therapy; tremelimumab
references.citation: Nat Rev Drug Discov. 2013 Jul;12(7):489-92
references.pmid: 23812256
references.citation: Cancer Immunol Immunother. 2013 Jun;62(6):1021-8
references.pmid: 23591982
references.citation: Eur J Cancer. 2013 Sep;49(14):2965-7
references.pmid: 23890942
references.citation: Semin Oncol. 2010 Oct;37(5):460-7
references.pmid: 21074061
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7412-20
references.pmid: 19934295
references.citation: Lancet Oncol. 2014 Jan;15(1):e1-2
references.pmid: 24384489
references.citation: Lung Cancer. 2012 Mar;75(3):360-7
references.pmid: 21937142
references.citation: Ann Oncol. 2004 Feb;15(2):257-60
references.pmid: 14760119
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2636-44
references.pmid: 12860938
references.citation: Lancet Oncol. 2013 Oct;14(11):1104-1111
references.pmid: 24035405